血动力学力量预测心力衰竭患者治疗sacubitril/valsartan的重塑和结果
Iacopo Fabiani1, Nicola Riccardo Pugliese2, Gianni Pedrizzetti3,4
1Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
ESC heart failure
|July 18, 2023
概括
血动力学力 (HDFs) 来自心声学,特别是整个心脏周期LV强度 (wLVS),预测心力衰竭中心力衰竭患者 (HFrEF) 治疗sacubitril/valsartan的反应. 增加wLVS也预测了更好的心血管结果.
科学领域:
- 心脏病学 心脏病学
- 心声回声扫描 (Echocardiography) 是一种心声回声扫描.
- 心脏衰竭管理的管理
背景情况:
- 已经提出了一种使用回声衍生的血液动力学力 (HDFs) 评估左心室 (LV) 系统-透气功能的新工具.
- 减少喷射分数 (HFrEF) 的心力衰竭是一个重大的临床挑战,需要有效的治疗策略.
研究的目的:
- 评估HFrEF患者对萨库比特里尔/瓦尔沙坦6个月治疗反应的HDF预测值.
- 评估HDFs在接受sacubitril/valsartan治疗的HFrEF患者中预测心血管事件的能力.
主要方法:
- 89名HFrEF患者开始使用sacubitril/valsartan进行了全面的评估,包括对HDF分析的心声学.
- 治疗反应被定义为临床改善,N-终端亲B型尿素的减少和/或LV射出分数的增加.
- 随访患者的综合终点是HF住院,心房动和心血管死亡.
主要成果:
- 51%的患者对萨库比特里尔/瓦尔沙坦有反应.
- 基线整个心脏周期LV强度 (wLVS) 在响应者中显著更高,是响应的唯一独立预测因子.
- 6个月后wLVS的增加 (ΔwLVS) 有效预测了预后,并降低了心血管事件的风险.
结论:
- HDF分析,特别是wLVS,是预测HFrEF中sacubitril/valsartan治疗反应的一个有价值的工具.
- 从HFrEF衍生的参数可以帮助优化HFrEF管理的临床决策.
更多相关视频
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
6.5K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
01:22Heart Failure Drugs: β-Blockers
367
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
367